Table 1.
Baseline Characteristics
| Characteristics | Overall (N = 38) |
|---|---|
| Age, years (mean ± SD) | 54.7 ± 10.2 |
| Gender, n (%) | |
| Female | 18 (47.4) |
| Male | 20 (52.6) |
| Race, n (%) | |
| Caucasian | 37 (97.4) |
| Hispanic | 1 (2.6) |
| Weight, kg (mean ± SD) | 103.5 ± 18.2 |
| Body mass index, kg/m2 (mean ± SD) | 35.6 ± 6.4 |
| Diabetes duration, years (mean ± SD) | 13.9 ± 8.8 |
| HbA1C, % (mean ± SD) | 10.1 ± 1.8 |
| % Time in range (70–180 mg/dL) (mean ±SD) | 57.0 ± 29.9 |
| % Time above range (>180 mg/dL)a (mean ± SD) | 43.1 ± 30.5 |
| % Time above range (>250 mg/dL)a (mean ± SD) | 15.8 ± 22.9 |
| Average glucose, mg/dL (mean ± SD) | 180.1 ± 47.3 |
| % Glucose CVb (mean ± SD) | 24.6 ± 5.9 |
| Medications | |
| Sulfonylurea, n (%) | 15 (39) |
| Metformin, n (%) | 21 (55) |
| Thiazolidinedione, n (%) | 5 (13) |
| DPP-4 Inhibitor, n (%) | 12 (32) |
| GLP-1 agnonist, n (%) | 9 (24) |
| SGLT-2 inhibitor, n (%) | 2 (5) |
| Basal insulin, n (%) | 16 (42) |
a
Two subjects' % time above range (>180 mg/dL), % time above range (>250 mg/dL) at baseline were missing.
b
Three subjects' %CV at baseline were missing.
CV, coefficient of variation; SD, standard deviation.